Cancer is the leading cause of death worldwide and this trajectory is predicted to continue for two decades¹. In 2012, an estimated 14.1 million new cases of cancer occurred worldwide. The four most common cancers are lung, female breast, bowel and prostate cancer. New therapeutic targets are providing cancer patients with improved outcomes and better quality of life. Boehringer Ingelheim is committed to developing targeted therapies for solid tumours and haematological malignancies and our  oncology research focuses on three areas: angiogenesis inhibition, signal transduction inhibition and cell-cycle kinase inhibition.